Not Signed In -
Organ Transplant |
|
|
Clinical Trial: A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation
This study is no longer recruiting patients.
|
Purpose
Facilited access to everolimus until it is commercially available and reimbursible by approprite parties
| Condition | Intervention | Phase |
|---|---|---|
| Solid organ transplantation | Drug: Everolimus (RAD) | Phase IV |
MedlinePlus consumer health information
Study Type: Interventional
Study Design: Treatment, Non-Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety Study
Further Study Details:
Study start: January 2004
Eligibility
Ages Eligible for Study: 18 Years - 70 Years, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Male or female recipients of solid organ transplants
- Subject is currently enrolled in an everolimus (RAD) trial sponsored by Novartis
- Currently on investigational drug everolimus (RAD) therapy
Exclusion Criteria:
- Inability or unwillingness to comply with immunosuppressive regimen.
- Pregnancy.
- History of acute organ rejection within the last 3 months.
Other protocol-defined inclusion/exclusion criteria may apply.
Location Information
Study chairs or principal investigators
Novartis, Study Director, Novartis
More Information
Study ID Numbers: CRAD001A2401
Last Updated: September 7, 2005
Record first received: September 6, 2005
ClinicalTrials.gov Identifier: NCT00149981
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-09-13
Last Updated: September 7, 2005
Record first received: September 6, 2005
ClinicalTrials.gov Identifier: NCT00149981
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-09-13
Resources
- A Transplant Center//'s Dedicated Duo (Cleveland Clinic)
- Organ Donation and Transplantation (Cleveland Clinic)
email this page
print this page
bookmark this page
feedback on this page
